ENDO 2021: BridgeBio Pharma Has Proof-of-Concept Data of Encaleret in Hypocalcemia

 

• Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept
• At Doses up to 180 mg Twice Daily, Encaleret was Well-Tolerated with No Serious Adverse Events and No Adverse Events of Moderate or Severe Intensity Reported After 5 Days
• Company to Host Webcast to Discuss Data on March 22 at 8:00 a.m. ET

BridgeBio will host a conference call and simultaneous webcast to share updates on the encaleret proof-of-concept data in ADH1 on March 22 at 8:00 a.m. ET. To access this call, dial (800) 379-2666 (U.S.) or (409) 937-8964 (International). Conference ID: 7371879. A link to the webcast may be accessed from the event calendar page of BridgeBio’s website at https://investor.bridgebio.com/. A replay of the conference call and webcast will be archived on the Company’s website and will be available for at least 30 days following the event.

https://www.biospace.com/article/releases/bridgebio-pharma-announces-proof-of-concept-data-of-encaleret-in-adh1-at-the-endocrine-society-s-2021-annual-meeting/